Adaptative Strategy of Immunosuppressive Drugs Dosage Adjustments When Combined With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients With COVID-19
Transplant International · 2024
DOI: 10.3389/ti.2024.12360 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant International, 2024. Verfasst von Lidvine Boland und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Chemistry, Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, Belgium. Hauptthemen laut MEDLINE: COVID-19, Organ Transplantation, Lactams, Leucine. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Nirmatrelvir/ritonavir is a promising option for preventing severe COVID-19 in solid organ transplant recipients with SARS-CoV-2 infection. However, concerns have arisen regarding potential drug interactions with calcineurin inhibitors (CNI). This two-phase multicentre retrospective study, involving 113 patients on tacrolimus and 13 on cyclosporine A, aimed to assess the feasibility and outcomes of recommendations issued by The French societies of transplantation (SFT) and pharmacology (SFPT) for CNI management in this context. The study first evaluated adherence to recommendations, CNI exposure, and clinical outcomes. Notably, 96.5% of patients on tacrolimus adhered to the recommendations, maintaining stable tacrolimus trough concentrations (C 0 ) during nirmatrelvir/ritonavir treatment. After reintroduction, most patients experienced increased C 0 , with 42.9% surpassing 15 ng/mL, including three patients exceeding 40 ng/mL. Similar trends were observed in cyclosporine A patients, with no COVID-19-related hospitalizations. Moreover, data from 22 patients were used to refine the reintroduction strategy. Modelling analyses suggested reintroducing tacrolimus at 50% of the initial dose on day 8, and then at 100% from day 9 as the optimal approach. In conclusion, the current strategy effectively maintains consistent tacrolimus exposure during nirmatrelvir/ritonavir treatment, and a stepwise reintroduction of tacrolimus may be better suited to the low CYP3A recovery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Chemistry, Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, Belgium.
- Louvain Centre for Toxicology and Applied Pharmacology (LTAP), Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Louvain-la-Neuve, Belgium.
- Department of Nephrology, Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, Belgium.
- Service de Pharmacologie, Toxicologie et Pharmacovigilance, Centre Hospitalier Universitaire de Limoges, Limoges, France.
- INSERM U1248 Pharmacology and Transplantation, Limoges, France.
- FHU SUPORT, Limoges, France.
Zitieren
APA
Boland, L., Devresse, A., Monchaud, C., Briol, S., Belaiche, S., Giguet, B., Couzi, L., Thaunat, O., Esposito, L., Meszaros, M., Roussoulieres, A., Haufroid, V., Le Meur, Y., & Lemaitre, F. (2024). Adaptative Strategy of Immunosuppressive Drugs Dosage Adjustments When Combined With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients With COVID-19. Transplant International. https://doi.org/10.3389/ti.2024.12360
Vancouver
Boland L, Devresse A, Monchaud C, Briol S, Belaiche S, Giguet B, et al. Adaptative Strategy of Immunosuppressive Drugs Dosage Adjustments When Combined With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients With COVID-19. Transplant International. 2024. doi:10.3389/ti.2024.12360
BibTeX
@article{Boland2024,
author = {Boland, Lidvine and Devresse, Arnaud and Monchaud, Caroline and Briol, Sébastien and Belaiche, Stéphanie and Giguet, Baptiste and Couzi, Lionel and Thaunat, Olivier and Esposito, Laure and Meszaros, Magdalena and Roussoulieres, Ana and Haufroid, Vincent and Le Meur, Yannick and Lemaitre, Florian},
title = {Adaptative Strategy of Immunosuppressive Drugs Dosage Adjustments When Combined With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients With COVID-19},
journal = {Transplant International},
year = {2024},
doi = {10.3389/ti.2024.12360}
}
EUVIMED